Senior Director, Head of Global Technical Leader

OXB is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Join Us in Changing Lives At OXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. We are currently recruiting for a Head of Global Technical Leader. The purpose of the role is to lead and develop OXB’s Global Technical Leaders team to ensure world‑class technical capability, introduce strategic technologies, and drive an innovation‑led service offering for our global viral vector CDMO business, playing a key part in advancing our mission and making a real difference. This role can be located close by one of our global locations in Oxford, UK, Bedford, MA or Durham, NC, US, or Strasbourg or Lyon in France. Your responsibilities in this role would be:

• Lead, develop and manage the Global Technical Leader (TechLead) team to ensure high performance and technical capability.
• Provide global oversight of OXB’s technology platforms across process and analytics.
• Drive the introduction of new technologies by partnering with Innovation, Process Development, Strategy and Global MSAT.
• Chair and manage the Technology Platforms Committee to ensure alignment and effective decision‑making.
• Define, communicate and maintain the company’s services portfolio and ensure it evolves with platform developments.
• Collaborate with Strategy to evaluate new modality opportunities.
• Act as CMC Lead for late‑phase programs, ensuring phase‑appropriate readiness for clinical and future commercial use.
• Integrate customer feedback to optimise technology platforms and enhance service offerings.

We are looking for:

• Degree in a relevant scientific discipline; a postgraduate degree or PhD is strongly preferred.
• Experience working in a global CDMO or biopharma environment.
• Strong technical expertise in viral vector technologies, including process operations, analytics, equipment and gene delivery approaches.
• Comprehensive understanding of regulatory frameworks such as cGMP and ICH.
• Proven ability to deliver new technical capabilities and drive innovation.
• Strong strategic, analytical and commercial thinking skills.
• Experience in client‑facing roles and use of CRM tools (e.g., Salesforce).
• Demonstrated experience leading and developing high‑performing technical teams

The US salary range for this position: $171k - $220k per year. This offer range represents the anticipated base pay compensation for this position. The actual compensation offered will be determined by factors such as location, level of experience, education, skills, and other job-related factors. Position may be eligible for performance-based bonuses. Benefits offered by OXB include health insurance, 401k contributions, paid time off (PTO) and tuition reimbursement. This role does not offer sponsorship for work authorization. External applicants must be eligible to work in the United States. About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 30 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. Why Join Us?

• 💸 Competitive total reward packages
• 🧘 Wellbeing programs that support your mental and physical health
• 🚀 Career development opportunities to help you grow and thrive
• 🤝 Supportive, inclusive, and collaborative culture
• 🧪 State-of-the-art labs and manufacturing facilities
• 🌍 A company that lives its values: Responsible, Responsive, Resilient, Respect

We want you to feel inspired every day. At OXB, we’re future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.